Skip to main content
Fig. 4 | BMC Nephrology

Fig. 4

From: Tailored immunosuppression after kidney transplantation - a single center real-life experience

Fig. 4

Induction therapies and rejection-free survival. a Distribution of the different induction therapies in the whole study group (n = 204 patients). b Comparison of acute rejection-free survival between patients with and without any type of induction therapy. c Comparison of acute rejection-free survival between the two most important induction therapies thymoglobulin and basiliximab (p = 0.656). Acute rejection rates after 12 months were 22.9% for thymoglobulin, 28.4% for basiliximab and 40.6% for the no induction group

Back to article page